IBB:NSD-iShares Nasdaq Biotechnology Index Fund (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 136.1

Change

+1.91 (+1.42)%

Market Cap

USD 8.53B

Volume

0.74M

Analyst Target

N/A
Analyst Rating

Sell

ducovest Verdict
Created with Highstock 5.0.6

Slightly Bearish

About

The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of NASDAQ? listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Inception Date: 05/02/2001

Primary Benchmark: NASDAQ Biotechnology TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.47%

Management Expense Ratio: 0.47 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Created with Highstock 5.0.6
Cash (0%)
NotClassified (0%)
Stock non-US (9%)
Other (0%)
Stock US (90%)
Bond (0%)
Top Holdings

N/A

Top Sectors

N/A

Created with Highstock 5.0.6
Basic Materials (0%)
Consumer Cyclicals (0%)
Financial Services (0%)
Real Estate (0%)
Communication Services (0%)
Energy (0%)
Industrials (0%)
Technology (0%)
Consumer Defensive (0%)
Healthcare (100%)
Utilities (0%)
Top Regions

N/A

Created with Highstock 5.0.6
North America (91%)
United Kingdom (1%)
Europe Developed (5%)
Europe Emerging (0%)
Africa/Middle East (0%)
Japan (0%)
Australasia (0%)
Asia Developed (0%)
Asia Emerging (1%)
Latin America (0%)

Share Volume

Relative Performance (Total Returns)

Compare
IBB QQQ
  • QQQ
Relative Returns (From:    To: 2025-03-17 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
PPH VanEck Pharmaceutical ETF 0.36 %

+0.19 (+0.20%)

USD 0.60B
BBH VanEck Biotech ETF 0.35 %

-1.79 (-1.09%)

USD 0.39B
PSCH Invesco S&P SmallCap Health Ca.. 0.29 %

-0.44 (-1.03%)

USD 0.19B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

-0.97 (-2.41%)

USD 0.13B
GNOM Global X Genomics & Biotechnol.. 0.00 %

-0.29 (-3.26%)

USD 0.06B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

-0.12 (-0.43%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %

-0.30 (-2.77%)

USD 9.96M

ETFs Containing IBB

IBB3:LSE 300.12 % 0.00 %

N/A

N/A
HAC.A:CA 0.00 % 3.14 %

N/A

N/A
HAC:CA Global X Seasonal Rotatio.. 0.00 % 1.27 %

N/A

CAD 0.21B
IBBS:LSE -299.94 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.94% 63% D 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.94% 63% D 74% C
Trailing 12 Months  
Capital Gain 0.62% 63% D 54% F
Dividend Return 0.29% 50% F 4% F
Total Return 0.91% 50% F 51% F
Trailing 5 Years  
Capital Gain 38.41% 50% F 48% F
Dividend Return 1.80% 43% F 3% F
Total Return 40.22% 38% F 44% F
Average Annual (5 Year Horizon)  
Capital Gain -0.95% 38% F 36% F
Dividend Return -0.70% 38% F 33% F
Total Return 0.24% 50% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 19.92% 75% C 77% C+
Risk Adjusted Return -3.54% 38% F 32% F
Market Capitalization 8.53B 100% F 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.